…simply getting back to its five-year average [P/E] multiple of 11.7 times would put Bristol stock at $91.38…while getting to Merck’s 13 times would put the shares at $101.53…
BMY's performance in 2022 YTD has been pretty good, but the stock is still cheap.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”